ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-GPRC5D Monoclonal Antibody SAR446523

In Sanofi’s pipeline, GPRC5D mAb. Its studies are mostly in Multiple Myeloma, led by Sanofi.

Furthest: phase 1, since Oct 3, 20241 company-led study, 1 open or runningNext primary completion: May 16, 2031 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi11 open or runningphase 1since Oct 3, 2024Oct 3, 2024May 16, 2031phase 1 · NCT06630806
  • Named in Sanofi’s own pipeline as SAR446523, phase 1, as of Sep 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 3, 2024First study: phase 1 study in Plasma Cell Myeloma RefractoryFirst studyNCT06630806 · 87 planned · United States, Australia, Canada and more

Ahead

  1. May 16, 2031Primary completion: phase 1 study in Plasma Cell Myeloma RefractoryNCT06630806

TargetBeta

“GPRC5D mAb”the company's pipeline, read by Claude · source
“A Fc-engineered immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) human G-protein coupled receptor family C group 5 member D (GPRC5D), with potential immunomodulating and antineoplastic activities. Upon administration, anti-GPRC5D monoclonal antibody…”NCIt, read by Claude

Other programs on GPRC5D

ProgramCompanyFurthest phaseStudies
ramantamigJohnson & Johnsonphase 38
GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003ruleInnovent Biologicsphase 34
arlocabtagene autoleucelBristol-Myers Squibbphase 33
QLS4131ruleQilu Pharmaceuticalphase 33
QLS32015ruleQilu Pharmaceuticalphase 32
vemzatatug vedotinAstraZenecaphase 21
MBS314 for Injectionrulebeijing-mabworks-biotech-co-ltdphase 21
REGN17372ruleRegeneron Pharmaceuticalsphase 21
tunlucabtagene autoleucelBristol-Myers Squibbphase 11
TQB2029Sino Biopharmaceuticalphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06630806Plasma Cell Myeloma Refractory · United States, Australia, Canada and more1RecruitingMay 16, 203187

How it is read

Names in the registry

  • “SAR446523”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.